BR112018005855A2 - tratamento de doenças neurodegenerativas - Google Patents
tratamento de doenças neurodegenerativasInfo
- Publication number
- BR112018005855A2 BR112018005855A2 BR112018005855A BR112018005855A BR112018005855A2 BR 112018005855 A2 BR112018005855 A2 BR 112018005855A2 BR 112018005855 A BR112018005855 A BR 112018005855A BR 112018005855 A BR112018005855 A BR 112018005855A BR 112018005855 A2 BR112018005855 A2 BR 112018005855A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- methods
- neurodegenerative diseases
- signaling
- myd88
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000011664 signaling Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 101150053046 MYD88 gene Proteins 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1516905.5A GB201516905D0 (en) | 2015-09-24 | 2015-09-24 | Treatment of Neurodegenerative diseases |
| PCT/GB2016/052970 WO2017051188A1 (en) | 2015-09-24 | 2016-09-23 | Treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018005855A2 true BR112018005855A2 (pt) | 2018-10-16 |
Family
ID=54544061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018005855A BR112018005855A2 (pt) | 2015-09-24 | 2016-09-23 | tratamento de doenças neurodegenerativas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180263992A1 (enExample) |
| EP (1) | EP3352759A1 (enExample) |
| JP (1) | JP6893917B2 (enExample) |
| KR (1) | KR20180056695A (enExample) |
| CN (1) | CN108025005A (enExample) |
| AU (1) | AU2016329005A1 (enExample) |
| BR (1) | BR112018005855A2 (enExample) |
| CA (1) | CA2999390A1 (enExample) |
| EA (1) | EA201890647A1 (enExample) |
| GB (1) | GB201516905D0 (enExample) |
| MA (1) | MA42930A (enExample) |
| MX (1) | MX2018003619A (enExample) |
| WO (1) | WO2017051188A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016077595A1 (en) | 2014-11-12 | 2016-05-19 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
| GB201714307D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| GB201714311D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| GB201714316D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatement of neurodegenerative diseases |
| GB201714303D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatment of neurodegenerative diseases |
| CN108853111B (zh) * | 2018-08-07 | 2020-06-05 | 浙江大学 | 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN113694047A (zh) * | 2021-08-31 | 2021-11-26 | 杭州师范大学 | β-石竹烯在制备抗肿瘤药物中的应用 |
| WO2025152803A1 (zh) * | 2024-01-17 | 2025-07-24 | 四川大学 | 一种靶向traf6的多肽及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US257403A (en) * | 1882-05-02 | Electric lighting apparatus | ||
| US62342A (en) * | 1867-02-26 | Improved tool for the manufacture of paper bags | ||
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| CA2484797A1 (en) * | 2002-05-06 | 2003-11-13 | Washington University | Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway |
| JP4328500B2 (ja) * | 2002-07-25 | 2009-09-09 | 独立行政法人農業・食品産業技術総合研究機構 | 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品 |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| JP2006522124A (ja) * | 2003-04-03 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用な組成物 |
| ES2673158T3 (es) * | 2004-02-09 | 2018-06-20 | Mitsubishi Tanabe Pharma Corporation | Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA |
| RU2405566C9 (ru) * | 2005-02-03 | 2012-04-27 | Дзе Дженерал Хоспитал Корпорейшн | Способ лечения рака, устойчивого к гефитинибу |
| US7449442B2 (en) * | 2005-07-12 | 2008-11-11 | Children's Medical Center Corporation | EGFR inhibitors promote axon regeneration |
| JP2008061505A (ja) * | 2006-09-04 | 2008-03-21 | Hisamitsu Pharmaceut Co Inc | 筋萎縮性側索硬化症の治療剤のスクリーニング方法 |
| US8993615B2 (en) * | 2008-08-08 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
| CN102573500A (zh) * | 2009-08-06 | 2012-07-11 | 纽拉尔图斯制药公司 | 巨噬细胞相关疾病的治疗 |
| EP2490698A4 (en) * | 2009-10-22 | 2013-09-25 | Hoffmann La Roche | MODULATION OF AXONES DEGENERATION |
| WO2014018932A2 (en) * | 2012-07-27 | 2014-01-30 | Bunt Antonius Martinus Gustave | Effluz inhibitor compositions and methods of treatment using the same |
-
2015
- 2015-09-24 GB GBGB1516905.5A patent/GB201516905D0/en not_active Ceased
-
2016
- 2016-09-23 AU AU2016329005A patent/AU2016329005A1/en not_active Abandoned
- 2016-09-23 US US15/762,657 patent/US20180263992A1/en not_active Abandoned
- 2016-09-23 MA MA042930A patent/MA42930A/fr unknown
- 2016-09-23 WO PCT/GB2016/052970 patent/WO2017051188A1/en not_active Ceased
- 2016-09-23 JP JP2018516056A patent/JP6893917B2/ja not_active Expired - Fee Related
- 2016-09-23 CA CA2999390A patent/CA2999390A1/en not_active Abandoned
- 2016-09-23 MX MX2018003619A patent/MX2018003619A/es unknown
- 2016-09-23 BR BR112018005855A patent/BR112018005855A2/pt not_active Application Discontinuation
- 2016-09-23 KR KR1020187010855A patent/KR20180056695A/ko not_active Withdrawn
- 2016-09-23 EA EA201890647A patent/EA201890647A1/ru unknown
- 2016-09-23 EP EP16775842.4A patent/EP3352759A1/en not_active Withdrawn
- 2016-09-23 CN CN201680056062.1A patent/CN108025005A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA42930A (fr) | 2018-08-01 |
| CA2999390A1 (en) | 2017-03-30 |
| GB201516905D0 (en) | 2015-11-11 |
| US20180263992A1 (en) | 2018-09-20 |
| JP2018534259A (ja) | 2018-11-22 |
| KR20180056695A (ko) | 2018-05-29 |
| EA201890647A1 (ru) | 2018-09-28 |
| JP6893917B2 (ja) | 2021-06-23 |
| EP3352759A1 (en) | 2018-08-01 |
| AU2016329005A1 (en) | 2018-04-19 |
| WO2017051188A1 (en) | 2017-03-30 |
| MX2018003619A (es) | 2018-08-01 |
| CN108025005A (zh) | 2018-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018005855A2 (pt) | tratamento de doenças neurodegenerativas | |
| CL2020002018A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
| BR112017017727A2 (pt) | heterociclos bicíclicos como inibidores de fgfr4 | |
| BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
| GEP20217328B (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| BR112018000691A2 (pt) | inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
| MX2021008044A (es) | Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| MX384490B (es) | Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias. | |
| MX376201B (es) | Compuestos inhibidores de metaloenzima. | |
| BR112014017751A8 (pt) | compostos inibidores de metaloenzima, métodos de inibir e modular a atividade de metaloenzina, composições contendo os ditos compostos e uso dos ditos compostos | |
| DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
| MX2019002190A (es) | Uso de pridopidina para tratar distonías. | |
| BR112017025255A2 (pt) | métodos, produto, produto de programa de computador, sistema, e composições farmacêuticas estimulante e inibidora para uso no tratamento ou prevenção do câncer de próstata | |
| BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
| BR112016001781A2 (pt) | inibidores de rorc2 e métodos de uso dos mesmos | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| BR112018075135A2 (pt) | combinações farmacêuticas para tratar câncer | |
| CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
| MX395492B (es) | Usos terapeuticos de l-4 cloroquinurenina. | |
| BR112017024304A2 (pt) | processo para a preparação de um extrato de cérebro animal | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| BR112018012295A2 (pt) | glicoproteína v solúvel para tratar doenças trombóticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |